UNSPSC 51183202: Alogliptin benzoate

This classification denotes an anti-diabetic agent C18H21N5O2.C7H6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier EEN99869SC, chemically known as benzonitrile, 2-((6-((3r)-3-amino-1-piperidinyl)-3,4-dihydro-3-methyl-2,4-dioxo-1(2h)-pyrimidinyl)methyl)-, monobenzoate, but more generally known as alogliptin benzoate, which bears US NIH Compound Identifier 16088021. European Medicines Agency schedules Alogliptin benzoate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB32165.

UNSPSC 51183202 Alogliptin benzoate, a Commodity code, represents a single active pharmaceutical ingredient — a dipeptidyl peptidase-4 (DPP-4) inhibitor used in diabetes management — that state and local governments procure through their pharmacy benefit programs, correctional health systems, and public health clinics. The code captures finished pharmaceutical products containing this ingredient, typically acquired as part of bulk or formulary purchasing by Medicaid programs, state prison healthcare systems, county health departments, and municipal public health facilities.

The source provides no recent state and local contract opportunities tagged to UNSPSC 51183202. Pharmaceutical ingredients and finished drugs move through state procurement primarily via standing cooperative purchasing agreements (such as state pharmacy networks or group purchasing organizations) rather than discrete solicitations. When individual state or local health agencies do issue RFPs or RFQs for specific drug formulations, they typically route those through existing vendor panels or pre-negotiated contracts rather than posting standalone opportunities. Without posted opportunities in the recent-opportunities block, the activity level and geographic concentration under this code cannot be characterized from the available data.